AmbioPharm is Pharmaceuticals in United States that focus on generic peptides business. Founded in 2007. They cover business area such as manufacturer, active pharmaceutical ingredient, generic peptide, production, research-grade complex peptide generic pharmaceutical, pre-clinical in-vitro, medicinal and toxicology program, its responsive business model, rapid manufacturing process, pharmaceutical and biotech company, their peptide project, low cost.
2007
( 18 years old in 2025 )
Generic Peptides
-
1024 Dittman Court
North Augusta, SC 29842
United States
Private
manufactureractive pharmaceutical ingredientgeneric peptideproductionresearch-grade complex peptide generic pharmaceuticalpre-clinical in-vitro, medicinal and toxicology programits responsive business modelrapid manufacturing processpharmaceutical and biotech companytheir peptide projectlow cost
* We use standard office opening hours in near AmbioPharm's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
AmbioPharm is Pharmaceuticals business from United States that founded in 2007 (18 years old in 2025), AmbioPharm business is focusing on Generic Peptides.
AmbioPharm headquarter office and corporate office address is located in 1024 Dittman Court North Augusta, SC 29842 United States.
AmbioPharm was founded in United States.
In 2025, AmbioPharm is currently focus on generic peptides sector.
Above is snippet of Google Trends for "generic peptides" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with AmbioPharm, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
